J&J sales in US rise 10%, health care giant raises dividend
Johnson & Johnson beat first-quarter expectations, as growth in cancer treatments and the health care giant’s home market helped counter another revenue hit from the strong dollar Johnson & Johnson beat first-quarter expectations, as growth in cancer treatments and the health care giant's home market helped counter another revenue hit from the strong dollar. The Health care giant booked a $68 million loss on a one-time charge in the quarter related to its baby powder, and revenue grew more than 5% to $24.75 billion, which was better than anticipated. Sales in pharmaceuticals, the company’s largest Business , grew 4% in the quarter. The bulk of that revenue came from immunology and cancer treatments. Those include long-standing top sellers like the blood cancer treatment Darzalex and Stelara, which treats psoriasis and other inflammatory disorders. Aside from prescription drugs, Johnson & Johnson also sells medical devices, including products for knee and hip replaceme...